Stockwinners Market Radar for May 30, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:43 EDT Catalent director Buzy buys 44.5K shares of common stock - In a regulatory filing, Catalent disclosed that its President of Gene Therapy, Peter Buzy, bought 44.5K shares of common stock on May 29th. The total transaction size was $2.01M.

18:58 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Williams-Sonoma (WSM) up 11.5%... Okta (OKTA) up 8.1%... Yext (YEXT) up 4.6%... Marvell (MRVL) up 3.1%... Uber Technologies (UBER) up 2.6%. ALSO HIGHER: Coty (COTY) up 1.7% after chairman disclosed purchase of $4M in stock... Medicines Co. (MDCO) up 1.1% after Sarissa Capital disclosed 5.6% stake. DOWN AFTER EARNINGS: Zuora (ZUO) down 28.4%... Nutanix (NTNX) down 16.5%... The Gap (GPS) down 13.4%... Red Robin Gourmet (RRGB) down 12.7%... Scholastic (SCHL) down 9.7%... Zscaler (ZS) down 3.8%... Dell Technologies (DELL) down 3.3%... VMware (VMW) down 3.3%... Ulta Beauty (ULTA) down 3.1%... Costco (COST) down 1.4%. ALSO LOWER: Xbiotech (XBIT) down 9.0% after equity offering... Eversource Energy (ES) down 1.5% after equity offering. Movers as of 18:45ET.

18:52 EDT Teck Resources increases share buyback authorization to $1B - Teck Resources announced that it will apply an additional $600M of cash on hand to repurchase Class B subordinate voting shares under Teck's previously announced normal course issuer bid program, bringing the total share buyback announced since November 2018 to $1B. The $400M of share repurchases previously announced in November 2018 are now complete.

18:03 EDT Coty chairman buys 309K shares of common stock - In a regulatory filing, Coty disclosed that its chairman Peter Harf bought 309.2K shares of common stock on May 28th. The total transaction size was $4.03M.

17:57 EDT DOJ requires Amcor to divest medical packaging assets to proceed with Bemis deal - The Department of Justice announced that Amcor Limited (AMKR) will be required to divest three manufacturing facilities and other assets in order to proceed with its $6.8B acquisition of Bemis (BMS). The Department said that, without the divestiture, the proposed acquisition would eliminate competition between two of only three significant suppliers of three medical packaging products that are critical to the safe transportation and use of medical devices. The Department's Antitrust Division filed a civil antitrust lawsuit today in the U.S. District Court for the District of Columbia to block the proposed transaction. At the same time, the Department filed a proposed settlement that, if approved by the court, would resolve the Department's competitive concerns. Under the terms of the proposed settlement, Amcor must divest manufacturing facilities located in Ashland, Massachusetts; Milwaukee, Wisconsin; and Madison, Wisconsin; along with certain related assets, to Tekni-Plex Inc., or an alternate acquirer approved by the United States. Tekni-Plex is an international leader in flexible films and medical supplies.

17:38 EDT Hexcel director sells 6.1K shares of common stock - In a regulatory filing, Hexcel disclosed that its director Thierry Merlot sold 6.1K shares of common stock on May 28th. The total transaction size was $449.6K.

17:27 EDT Uber says Argentina showing 'strong signals' for growth - Says Argentina showing "strong signals" for growth. Says Argentina mostly a cash market at this point. Says growth in Italy is slowing. Says Spain growth has "taken a step back."

17:21 EDT Uber says has to focus on driver safety in Brazil - Says has to focus on driver safety in Brazil. Says moving away from cash is beneficial in most regions. Says U.S. brand damage will take time to repair.

17:08 EDT Uber says price increase will likely have impact on gross bookings growth - Says New York continues to grow on a dollar volume standpoint at a solid pace.

17:05 EDT Agnico Eagle reports commercial production achieved at Meliadine mine - Agnico Eagle Mines Limited reported that commercial production was achieved at the company's Meliadine mine on May 14. Located near Rankin Inlet, Nunavut, Canada, the Meliadine project was acquired in July 2010 and is Agnico Eagle's largest gold deposit in terms of mineral resources. The company owns 100% of the 111,358-hectare property. In February 2017, the company's board approved the construction of the Meliadine project. Expected production at Meliadine for 2019 remains unchanged at approximately 230,000 ounces of gold at total cash costs of $612 per ounce.

17:01 EDT Uber sees 'generational wave' cooling to car ownership - Says "a lot of capital coming in" for EATS segment. Says UberEATS category larger in China than rides category. Sees "generational wave" cooling to car ownership. Says thinks there will be consolidation in ride-sharing sector, but likes company's competitive chances.

17:00 EDT D.E. Shaw reports 5.0% passive stake in GoPro - D.E. Shaw disclosed a 5.0% stake in GoPro, which represents over 6.13M shares. The filing does not allow for activism.

16:55 EDT Uber says 2019 will be an 'investment year'

16:54 EDT Uber says plans to cut back on consumer promotions - Says plans to cut back on consumer promotions. Says there is a "natural expansion" that is happening around New York City, with 50% of rides not originating or ending in Manhattan. Sees contribution margin improving throughout 2019 due to decrease in competitive pressures. Says sees urbanization happening on global basis. Says 50% of EATS customers don't use rides.

16:51 EDT Uber sees Careem acquisition closing in January 2020 - Says "confident" in long-term models for global growth. Says Uber Freight (UBER) seeing progress with CVS (CVS) and Cisco (CSCO) on board. Says acquisition of Careem expected to close in January of 2020.

16:43 EDT Uber sees UberEATS popularity increasing ride share in Japan - Says UberFreight continues to make rapid progress in its expansion goals. Sees popularity of UberEATS increasing ride share in Japan.

16:36 EDT Gap drops nearly 11% after Q1 results

16:26 EDT Dell Technologies reports Q1 Infrastructure Solutions revenue down 5% at $8.2B - Reports Q1 Client Solutions revenue up 6% at $10.9B. Reports Q1 VMware revenue up 13% at $2.3B.

16:25 EDT Lamar Advertising - Lamar Advertising Company (LAMR) announced that Jay Johnson has been appointed CFO, effective October 1. Johnson has served as executive VP and CFO of DiamondRock Hospitality Company (DRH) since April 2018.

16:23 EDT TiVo announces Dave Shull as CEO - TiVo announced that its board unanimously elected Dave Shull to the position of president and CEO and a member of the board, effective May 31. Interim president and CEO Raghu Rau will then assume the role of vice chairperson on the company's board. Dave Shull has over 15 years of senior leadership experience in the Pay-TV, OTT and digital media fields. Most recently, he served as the CEO of The Weather Channel cable network, which was sold in a competitive bidding process in 2018.

16:18 EDT Landstar System appoints Robert Brasher Chief Commercial Officer - Landstar System announced that Robert Brasher has been appointed to succeed Patrick O'Malley as Landstar's VP and Chief Commercial Officer, effective June 3. The company also announced that O'Malley will step down from his current position with the company on May 31, and will serve as a special advisor to the CEO through his anticipated retirement in February 2020.

16:16 EDT Mercury Systems receives $3.9M contract - Mercury Systems announced it received a $3.9M development contract from a leading defense prime contractor to prepare next generation airborne radar processing subsystems for production at the company's secure and trusted Defense Microelectronics Activity-accredited manufacturing facility. The company expects that the contract will be fulfilled by the end of the calendar year.

16:15 EDT Okta announces new Asia Pacific infrastructure, new office in Germany - Okta (OKTA) announced new Amazon (AMZN) Web Services-based Okta infrastructure available in the Asia Pacific region and the opening of its first office in Germany to support its global customer base. Together, the investments showcase international expansion for the San Francisco-based company. The new Okta infrastructure is located in Sydney, Australia and will allow organizations in APAC to utilize the benefits of the Okta identity cloud by offering closer geographic proximity to their data. The investment follows the recent appointment of Graham Sowden as GM for APAC and represents the foundation of Okta's long-term strategy for growth in the region. The location in Australia leverages multiple data centers and cloud infrastructure provided by Amazon Web Services, built with the samey architecture design as Okta's U.S. infrastructure.

16:13 EDT Uber reports Q1 LATAM revenue $450M, down 13% - Reports Q1 U.S. and Canada revenue $1.75B, up 26%. Reports Q1 EMEA revenue $487M, up 26%. Reports Q1 APAC revenue $267M, up 6%.

16:09 EDT Marvell CEO says taking 'bold steps despite challenging environment' - CEO Matt Murphy says: "Marvell continues to take bold steps despite a challenging near-term environment to improve our portfolio through strategic capital deployment and drive long term shareholder value. With the production ramp of our first 5G products later this year, and a growing pipeline of new wireless infrastructure design wins, Marvell is well positioned to becoming a leading silicon supplier to this market."

16:07 EDT DiamondRock CFO Jay Johnson to become Lamar Advertising CFO on August 31st - DiamondRock's (DRH) Executive VP & CFO, Jay Johnson, will be stepping down from his role effective August 31, in order to assume the position of CFO of Lamar Advertising Company (LAMR) in Baton Rouge, Louisiana. Johnson has served as DiamondRock's CFO since April 1, 2018. The company expects to name a new CFO before Johnson's scheduled departure on August 31.

16:06 EDT NanoString partners with multiple leading contract research organizations - NanoString Technologies announced commercial partnerships with three Contract Research Organizations, including Covance, NeoGenomics Laboratories, Inc., and Navigate BioPharma Services, to expand access to NanoString's PanCancer IO 360 Gene Expression Panel. The IO 360 Panel profiles the complex interplay between the tumor, microenvironment, and immune response in cancer. Developed specifically for translational research, the IO 360 Panel allows for a multifaceted characterization of disease biology and interrogation of multiple mechanisms of immune evasion. NanoString's partnerships with each of these leading CROs will focus on two priorities. Firstly, NanoString will enable the CRO partners to offer and deliver a standardized research report which currently captures 47 gene expression signatures measuring the activity and abundance of immune and tumor cells. Secondly, NanoString has provided each CRO the rights to independently develop, validate, and offer, within their CLIA-licensed lab, translational research assays based upon the 18-gene Tumor Inflammation Signature as described in The Journal of Clinical Investigation. Tumor inflammation is an increasingly important method to characterize tumors based upon the level of immune infiltration and function.

14:47 EDT GE CEO says power business to cut costs by about 20% over next 2 years

14:37 EDT GE CEO sees 'modest' cash flow pressures from Boeing 737 MAX grounding - Sees "modest" cash flow pressures from 737 MAX grounding. Says demand in gas power business has taken a step down in recent years. Says gas isn't going away, but is being used differently.

14:26 EDT GE CEO says 'hopeful' about resolution of U.S.-China trade talks soon - Says would consider M&A after stabilizing and strengthening the overall company. Says does about 7%-8% revenue in China. Says has long-standing public record of being for free and fair trade. Says "hopeful" about resolution of U.S.-China trade talks soon. Says some concerns around access in trade are real. Says hasn't really seen negative impact on businesses from trade war beyond some pressure from tariffs. Says GECAS jet leasing business "not for sale" right now.

13:17 EDT Clean Harbors Chairman Alan McKim sells over $2.5M in company shares - Clean Harbors Chairman Alan McKim disclosed in a filing that he had sold 38,682 shares of company stock at an average price of $65.32 per share on May 28. The total transaction value of the sale was $2,526,708.

13:03 EDT Activision Blizzard announces Modern Warfare launches October 25th - Activision Blizzard said in a statement; "Prepare to go dark, Modern Warfare is back! The most celebrated series in Call of Duty will make its highly-anticipated return when Call of Duty: Modern Warfare launches October 25th in a powerful experience reimagined from the ground-up. The all-new title, published by Activision and developed by Infinity Ward, engulfs players in a modern-day conflict, where split-second decisions could affect the global balance of power. The new Modern Warfare features a unified narrative experience and progression across a heart racing, epic single-player story, an action-packed multiplayer playground, and new cooperative gameplay. "This is an all-new Modern Warfare reimagined in every way," said Dave Stohl, co-Studio Head, Infinity Ward. "We are creating an emotionally charged experience that's inspired by the headlines in the world today, where the rules are grey and battle lines are blurred. Players will join a varied cast of international special forces and freedom fighters in gripping and heart-pounding missions through iconic European cities and volatile expanses of the Middle East. It's intense, it's exciting, and we can't wait for our fans to play this October."

12:54 EDT Global shipments of wearable devices reached 49.6M units in Q1, IDC says - Global shipments of wearable devices reached 49.6 million units during the first quarter of 2019, up 55.2% from the previous year according to data from the International Data Corporation Worldwide Quarterly Wearable Device Tracker. While wrist-worn wearables accounted for the majority of the market with 63.2% share, ear-worn devices experienced the fastest growth and accounted for 34.6% of all wearables shipped. Apple (AAPL) maintained the leading position as the company offers three product lines; Apple Watch, AirPods, and select Beats headphones. The launch of Samsung's (SSNLF) Galaxy S10 lineup helped the company propel its wearables business through the use of bundling. Fitbit (FIT) rounded out the top 5 and maintained its positive growth trajectory, IDC said. The recent launch of the Versa Lite as well as the Inspire series has helped the company reach new users as well as encouraged upgrades, although this has come at the expense of a lower ASP.

12:38 EDT Intelligent Systems falls after second short report questions financials - Shares of Intelligent Systems are down after the company was the subject of a second short report in week. Following Aurelius Value's report on May 24, Grizzly Research posted a short report today on its website. Grizzly, which says it produces "differentiated research insights on publicly traded companies through in-depth due diligence," put a $5 price target on shares of Intelligent Systems. The stock in midday trading is down 17%, or $5.85, to $27.96. "We believe that Intelligent Systems Corp. has its employees set up or take control of undisclosed shell companies in Asia, who then partake in undisclosed related party transactions with INS intended to either round-trip revenue back to INS or siphon money out of the company," Grizzly said in its report. The firm believes "these material undisclosed related party transactions cast doubt on the integrity of INS's financial statements."

12:37 EDT Aramark jumps after Reuters report of private equity takeover interest - Shares of Aramark (ARMK) spiked in early afternoon trading after Reuters reported that investment firm Mantle Ridge is exploring making an offer to acquire the U.S. food services company along with a consortium of others. If so, Mantle Ridge would be attempting one of the biggest leveraged buyouts since the financial crisis, the report noted. Following the report, Aramark shares are up nearly 8% to $35.27.

12:22 EDT Cemex completes deployment of CEMEX Go platform worldwide - CEMEX announced that it has completed the deployment of its CEMEX Go platform worldwide. CEMEX is committed to proactively developing innovative products and cutting-edge solutions to help fulfill its customers' business needs. The ongoing success of CEMEX Go is a testament to the company's customer-centric commitment and relentless focus on continuous innovation and improvement. Ignacio Madridejos, President of CEMEX USA said: "CEMEX Go has proven to be a game changer for our customers, allowing them to have better control of their businesses by providing them the information they need, anytime they need it. We're proud to be leading the way in digital technology in the the building materials industry, innovating to provide a superior customer experience by creating a tool that's become essential for our customers."

12:00 EDT Designer Brands rises 11.1% - Designer Brands is up 11.1%, or $1.99 to $19.98.

12:00 EDT Veeva rises 14.8% - Veeva is up 14.8%, or $19.96 to $154.45.

11:12 EDT Twitter introduces live video broadcast feature with live audio guests - In a video tweet published to its feed on May 29, Twitter posted "Go live with guests! It's more fun than talking to yourself. We promise." The video shows a live video broadcast with a "guest" joining in on the broadcast with audio only. This is done natively on Twitter and not through Periscope, Twitter's video app. Reference Link

11:05 EDT JPMorgan's Smith says trade war to have 'meaningful' impact on economy - Gordon Smith, JPMorgan's co-president and COO, says U.S. consumer, economy "looks to be in really strong shape" right now. Comments taken from Bernstein's 35th Annual Strategic Decisions Conference.

11:01 EDT Rite Aid names Erik Keptner chief marketing and merchandising officer - Rite Aid Corporation announced that Erik Keptner, a proven leader with more than 20 years' experience in retail marketing, has been named to the newly created position of senior vice president and chief marketing and merchandising officer, effective June 24, 2019. In this position, Keptner will be responsible for all aspects of marketing and merchandising. He will report to Bryan Everett, Rite Aid's COO. Keptner most recently served as senior vice president of marketing for Keasbey, N.J.,-based Wakefern Food Corporation.

10:00 EDT Myovant Sciences falls -12.4% - Myovant Sciences is down -12.4%, or -$1.49 to $10.52.

10:00 EDT Burlington Stores rises 10.1% - Burlington Stores is up 10.1%, or $14.81 to $160.81.

10:00 EDT Veeva rises 12.6% - Veeva is up 12.6%, or $17.01 to $151.50.

09:47 EDT PVH Corp. falls -9.7% - PVH Corp. is down -9.7%, or -$9.65 to $89.60.

09:47 EDT Movado falls -12.8% - Movado is down -12.8%, or -$3.94 to $26.77.

09:47 EDT Designer Brands rises 11.2% - Designer Brands is up 11.2%, or $2.01 to $20.00.

09:27 EDT Wells Fargo: Search committee seeking CEO with 'proven record of leadership'

09:22 EDT Reebonz Holding launches sell back guarantee in Thailand - Reebonz Holding announced that it has launched its sell back guarantee service in Thailand. With this addition, Reebonz aims to deepen its relationship with customers in Thailand. The sell back guarantee service leverages the trade-in concept and gives customers a guaranteed price that the company will pay to buy back products that were initially sold on its platform. Customers will be offered currency, called Reebonz credits, that can be used for future purchases on the platform. Reebonz has expanded the categories for which the sell back guarantee applies from leather goods to jewelry. Pre-owned jewelry from selected brands will be eligible. The sell back guarantee is now available in Singapore, Hong Kong, Taiwan, Malaysia, Australia, Indonesia, and the United States.

09:20 EDT Wells Fargo's Parker says not yet at third-party review stage of asset cap

09:16 EDT Diana Shipping announces time charter contract for m/v Leto with Uniper - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Uniper Global Commodities for one of its Panamax dry bulk vessels, the m/v Leto. The gross charter rate is $13,000 per day, minus a 5% commission paid to third parties, for a period of minimum 11 months to maximum 13 months. The charter is expected to commence on May 31. The m/v Leto is currently chartered, as previously announced, to Glencore Agriculture at a gross charter rate of $12,500 per day, minus a 5% commission paid to third parties. This employment is anticipated to generate approximately $4.29M of gross revenue for the minimum scheduled period of the time charter.

09:14 EDT Neuberger Berman issues presentation to Verint shareholders - Neuberger Berman Investment Advisers and certain of its affiliates that manage investment funds and client accounts that collectively own approximately 1.74M shares, or 2.7%, of the outstanding stock of Verint Systems announced that it has issued a presentation to Verint's shareholders. Neuberger Berman encourages its fellow shareholders to review the presentation, its proxy materials, and its shareholder letters, all of which are available at www.BetterVerint.com.

09:10 EDT Wells Fargo says has in place 'the leaders we need' to drive process forward

09:05 EDT Tyson Foods appoints Noelle O'Mara CMO - Tyson Foods has appointed Noelle O'Mara to the newly created role of chief marketing officer, or CMO. O'Mara, who has more than 17 years of food marketing experience, joined Tyson Foods in April 2016 as VP, new business models. She most recently served as general manager and senior VP of two of the company's billion dollar brands, Jimmy Dean and Tyson. In her new position, O'Mara reports to President and CEO Noel White and is responsible for innovation and brand building across the enterprise to support the company's overall growth strategy.

09:04 EDT MassMutual joins Benefitfocus Platform - Benefitfocus announced its newest BenefitsPlace insurance carrier partnership with MassMutual, a leading provider of voluntary benefits. Employers using the BenefitsPlace platform will now have the ability to elect to offer MassMutual's Universal Life and Whole Life insurance products, along with the company's innovative financial wellness tool, MapMyFinances.

08:50 EDT AbbVie to present over 40 data updates on oncology portfolio at ASCO, EHA - AbbVie announced it will present more than 40 data updates across its oncology portfolio during the upcoming American Society of Clinical Oncology Annual Meeting on May 31-June 4, in Chicago, and the European Hematology Association Annual Congress on June 13-16, in Amsterdam. The data presentations will span the company's investigational and approved oncology portfolio medicines in more than 15 different blood and solid tumor cancers. For the first time, researchers will also present data from the Phase 3 CLL14 study evaluating venetoclax plus obinutuzumab versus obinutuzumab plus chlorambucil at ASCO. Results from the trial supported the recent FDA approval of this VENCLEXTA chemotherapy-free combination for previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Researchers will also present new, multi-year, long-term data on the use of single-agent ibrutinib in CLL/SLL at both ASCO and EHA in 2019. Six years of follow-up data evaluating previously treated patients on ibrutinib therapy from the Phase 3 RESONATE trial will be presented as a poster discussion at ASCO, and more than five years of follow-up for previously untreated patients on ibrutinib therapy from the Phase 3 RESONATE-2 trial will be presented in an oral session at EHA. The RESONATE trial's long-term follow-up data presentation was also selected to be featured at the Best of ASCO 2019 Meetings, which highlight cutting-edge science and reflect the leading research and strategies in oncology. Following updates earlier this year, the National Comprehensive Cancer Network now recommends ibrutinib as a preferred regimen for the initial treatment of CLL/SLL and the only Category 1 single-agent regimen for patients without 17p deletion

08:46 EDT Windtree Therapeutics says istaroxime Phase 2b study achieves primary endpoint - Windtree Therapeutics announced the presentation of new safety and efficacy data from a phase 2b study of istaroxime in patients hospitalized with acute heart failure at a late-breaker session of the European Society of Cardiology. The study achieved its primary endpoint by demonstrating a significant improvement in cardiac function at both istaroxime study doses. The study further showed that stroke volume, a key secondary endpoint, was substantially increased. Importantly, certain toxicities and complications experienced with many existing acute heart failure therapies were not observed in istaroxime-treated patients, including no signals of increased arrhythmias or increased troponin levels, a common marker of heart muscle damage. Istaroxime significantly increased or maintained systolic blood pressure during treatment which may have contributed to a short-term trend toward improvement in renal function. The phase 2b study in 120 patients was designed to assess the safety and efficacy of 24-hour infusions of two doses of istaroxime, compared to placebo, in the treatment of patients with acute heart failure. The primary endpoint of this study was a change from baseline to 24 hours after start of infusion in E/e' with istaroxime 0.5 or 1.0 microg/kg/min vs. placebo. The E/e' ratio is a marker of the function of the left ventricle of the heart and was measured using doppler echocardiography read by a central laboratory. Secondary endpoints included change in other parameters of cardiac function, such as diastolic function, stroke volume, left ventricle ejection fraction, LV volumes, left atrial area, and interior vena cava diameter. Investigators of this study concluded that a 24-hour infusion of istaroxime was associated with significant improvements in cardiac function, in both dosing groups, with a mean E/e' of -4.55 for the 0.5 microg/kg/min group and -3.16 for the 1.0 microg/kg/min group, compared with mean placebo E/e' ratios of -1.55 and -1.08, respectively. Twenty-four-hour infusions of istaroxime were also associated with substantial increases in stroke volume in both dosing groups, with a mean SVI value of 5.33 ml/beat/m2 for the 0.5 microg/kg/min group and 5.49 ml/beat/m2 for the 1.0 microg/kg/min group, compared with the mean placebo SVI of 1.65 ml/beat/m2 and 3.18 ml/beat/m2, respectively. Importantly, subjects also maintained or increased systolic blood pressure, with a mean change in SBP of 2.82 mmHg for the 0.5 microg/kg/min group and 6.1 mmHg for the 1.0 microg/kg/min group, compared with the mean placebo SBP values of -2.47 mmHg and 2.7 mmHg, respectively. Istaroxime was generally well tolerated. Istaroxime did not appear to be associated with an increase in risk for arrhythmias or increases in cardiac troponin T. Cardiovascular related adverse events were 23 percent for placebo, 10 percent for istaroxime low dose, and 18 percent for istaroxime high dose with cardiac failure occurring in 3 percent, 5 percent and 8 percent of placebo, low and high dose of istaroxime patients, respectively. The most common adverse drug reactions reported included pain at infusion site, generally associated with use of short catheters, and dose-related gastrointestinal adverse events in 5 percent, 10 percent and 35 percent of placebo, low and high dose istaroxime, respectively.

08:38 EDT ADDvantage shareholders approve sale of cable TV business - ADDvantage announced that its shareholders voted to approve the sale of the company's cable TV segment at the special meeting. The shareholder proposal was approved by 99% of the 7.8M shares voted. The sale has been approved by the board and remains subject to the finalization of documentation, meeting certain customary closing conditions and the transfer of funding. The transaction is expected to close within the next 10 days. Specifically, ADDvantage's shareholders agreed to sell to Leveling 8 all of the outstanding shares and limited liability company membership interests, as applicable, of Tulsat, NCS Industries, ADDvantage Technologies Group of Missouri, ADDvantage Technologies Group of Texas and Tulsat-Atlanta, collectively referred to as the cable companies. Subject to certain post-closing adjustments, Leveling 8 will pay a total purchase price of $10.3M. The purchase price will consist of $3.9M of cash at closing, less $1.4M of cash previously received from the sale of the ComTech facility in March and a $6.4M promissory note bearing interest at 6% per annum. The note will be paid over five years and is personally guaranteed by David Chymiak, who is the 100% beneficial owner of Leveling 8, ADDvantage's CTO, President of Tulsat, substantial shareholder of the company and a member of the board.

08:36 EDT Luokung Technology, Land Space announce strategic partnership - Luokung Technology announced its strategic partnership with Land Space Technology Corporation. The two parties will work together and take advantage of respective strength on commercial space cooperation with satellite remote sensing data applications as the main target market. They will jointly develop domestic and foreign markets of products and services which are not limited to spatial-temporal big-data applications and aerospace application systems, and jointly build a measurement and control system for rockets, satellites and earth stations with global coverage. Land Space will cooperate with Luokung on developing the domestic and foreign launch service markets, remote sensing data application market, and target users in different market segments. Luokung can integrate its spatial-temporal cloud index technology and spatial-temporal big data processing and algorithm technology with the business of Land Space, which will provide stable, efficient and customized spatial-temporal cloud computing support for clients in the spatial temporal big data processing, analyzing, transmission and release services in internet and mobile internet. To build a global coverage measurement and control system for rockets, satellites and earth stations, Luokung will provide its world leading spatial-temporal cloud indexing technology, spatial-temporal big-data processing, algorithm and AI technology for real-time tracking analysis and display of position trajectory and attitude of rockets and satellites, to meet the needs of the global coverage of satellite services and mobile service universality as well as the requirements of overall network reliability and security, and to build a global information network with seamless coverage of space and earth

08:34 EDT Hologic partners with DEXA+ to distribute body composition measurement system - Hologic has signed an agreement with DEXA+ to distribute Hologic's Horizon DXA system for body composition measurement. DEXA+ works with healthcare practices nationwide to implement and optimize DXA technology to grow integrative medicine, health and wellness programs. The partnership expand the reach of Hologic's market-leading DXA system. Financial terms of the agreement were not disclosed.

08:25 EDT QAD Inc, Strategic Information Group partner for distribution rights in Ireland - QAD and Strategic Information Group have announced a partnership with QAD awarding Strategic full distribution rights to sell and service QAD ERP applications in the Republic of Ireland and Northern Ireland. Customers will benefit from QAD's next generation, cloud-based enterprise resource planning software applications combined with technology-related consulting services delivered through Strategic. QAD and Strategic also have a reseller partnership agreement in North America. For the past 27 years,

08:17 EDT Mack-Cali Realty calls Bow Street's statements 'misleading', 'outright lies' - Mack-Cali Realty Corporation responded to a letter sent by Bow Street Special Opportunities Fund XV to Mack-Cali stockholders. The company said, "During the course of its self-serving and deceptive campaign, Bow Street has repeatedly used false and misleading statements to disparage the Company's Board of Directors and disguise Bow Street's self-interested objectives...Mack-Cali believes it is important to set the record straight about the misleading statements and outright lies contained in Bow Street's letter...In its letter, Bow Street again claims that its objective is to create value for all Mack-Cali stockholders and attempts to portray itself as a long-term investor whose interests are aligned with those of long-term Mack-Cali stockholders. In reality, however, Bow Street is a recent stockholder who began to accumulate Mack-Cali shares just a few months before launching a proxy contest to facilitate its grossly inadequate, illusory, unfinanced and unworkable proposal to acquire the Company's premium office assets at a price far below their fair market value. Despite Bow Street's claims that it has "repeatedly called on the Board to establish a truly independent committee tasked with evaluating all strategic alternatives," Bow Street is not interested in any strategic alternatives other than a "fire sale" of the Company or its premium assets...In its letter, Bow Street falsely states that Mr. William Mack, Chairman of the Mack-Cali Board of Directors, "has competed directly against Mack-Cali for assets." These baseless claims are nothing more than deliberate lies designed to disparage Mr. Mack's character and reputation...In its letter, Bow Street falsely claims that over the last several weeks, the Mack-Cali Board was presented with "credible third-party proposals to acquire all or meaningful portions of Mack-Cali for all-cash consideration" and that the Board "explicitly discouraged suitors." These statements are outright lies...As previously announced, following the Company's upcoming Annual Meeting of Stockholders, the Mack-Cali Board intends to form a committee of independent directors to conduct a review of the Company's strategy, asset portfolio and business opportunities to ensure that all available alternatives for continuing stockholder value creation are carefully and thoughtfully considered. The Board's decision to form the Strategic Review Committee is the result of an ongoing, constructive dialogue between the Company and its stockholders and demonstrates that the Board remains open-minded and is not opposed to any action that is in the best interests of Mack-Cali stockholders. Contrary to Bow Street's baseless assertions, the Strategic Review Committee will have full authority to conduct an independent review of all available alternatives for maximizing stockholder value, including a potential sale of the Company... The Mack-Cali Board believes that the formation of the Strategic Review Committee will allow the Company to be responsive to the wishes of Mack-Cali stockholders and ensure that all available alternatives for maximizing stockholder value are carefully and thoroughly considered."

08:08 EDT Organovo collaborates to develop stem cell-based bioprinted tissue treatments - Organovo Holdings announced a collaboration with Professor Melissa Little at the Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia and Ton Rabelink at Universiteit Leiden, Leiden, Netherlands. The project will expand the use of 3D bioprinted stem cell-based therapeutic tissues to applications aimed at treating end-stage renal disease. This multi-organizational effort integrates Organovo's bioprinting platform with MCRI's advanced stem cell differentiation technology and LUMC's cell lines and clinical expertise. The collaboration has been made possible through generous funding from Stem Cells Australia and CSL Limited.

08:07 EDT Catalyst Pharmaceuticals expands Firdapse license to include Japan - Catalyst Pharmaceuticals announced that it has amended its license agreement for Firdapse to expand its commercial territory. The original license was for North America and has been amended to include Japan. Upon the achievement of a certain milestone in Japan, Catalyst will have the option to expand the territory further to include most of Asia and Central and South America. There are currently no approved therapies available to treat LEMS in Japan. In addition, Firdapse will seek to qualify for orphan drug designation in Japan. The original license was signed in October of 2012. Under the recently amended license, Catalyst will pay royalties of a similar percentage of its net revenues derived in Japan as in its original license agreement.

08:07 EDT eBay, CarAdvise partner to expand U.S. Tire Installation Program - eBay announced a partnership with CarAdvise, a vehicle repair and maintenance technology platform, to expand the marketplace's Tire Installation Program. The new partnership with CarAdvise initially adds 3,500 tire shops to eBay's tire installer network including top national chains like Firestone, Tires Plus, National Tire and Battery, and Tire Kingdom. Thousands of additional brand name shops within the CarAdvise network are slated to roll out over the coming months. eBay Motors' shoppers now have access to more than ten times the amount of current tire listings that offer installation services at check out, with even more added throughout the year.

08:04 EDT American Tower to acquire Eaton Towers Holding for about $1.85B - American Tower has entered into a definitive agreement to acquire Eaton Towers Holding, "which owns and operates approximately 5,500 communications sites across five African markets." As a result of the transaction, the company also expects to accelerate new build activity across the region due to expanded relationships with multiple key tenants. The total consideration for the transaction, including the company's assumption of existing Eaton Towers debt, is approximately $1.85B, subject to customary closing adjustments. The assets are expected to generate approximately $260M in property revenue and approximately $165M in gross margin, at current exchange rates, in their first full year in American Tower's portfolio. The transaction is anticipated to be immediately accretive to Consolidated AFFO per Share and is expected to close by the end of 2019.

08:02 EDT American Tower to acquire Eaton Towers Holding fr $1.85B - American Tower has entered into a definitive agreement to acquire Eaton Towers Holding, which owns and operates approximately 5,500 communications sites across five African markets. As a result of the transaction, the company also expects to accelerate new build activity across the region due to expanded relationships with multiple key tenants. The total consideration for the transaction, including the company's assumption of existing Eaton Towers debt, is approximately $1.85B, subject to customary closing adjustments. The assets are expected to generate approximately $260M in property revenue and approximately $165M in gross margin, at current exchange rates, in their first full year in American Tower's portfolio. The transaction is anticipated to be immediately accretive to Consolidated AFFO per Share and is expected to close by the end of 2019.

07:45 EDT Biogen announces new interim data from EVOLVE-MS-1 study - Biogen (BIIB) announced new interim data from the ongoing open-label EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis, or MS. Diroximel fumarate, an oral fumarate candidate in development with Alkermes (ALKS), is under review with the FDA with a Prescription Drug User Fee Act target action date in Q4. Biogen intends to market diroximel fumarate under the conditionally approved brand name Vumerity. EVOLVE-MS-1 is an ongoing, single-arm, open-label, two-year, Phase 3 study evaluating the safety and exploring the efficacy of diroximel fumarate in patients with relapsing-remitting MS. The study plans to enroll approximately 1,000 patients. Interim results from 696 patients treated with diroximel fumarate for a median of approximately one year were presented in safety and efficacy analyses at the CMSC meeting. Researchers explored the efficacy of diroximel fumarate in a sub-group analysis of EVOLVE-MS-1 that included patients naive to prior disease-modifying therapy treatment or those previously treated with an interferon, or IFN, or glatiramer acetate, or GA. New results in patients treated with prior IFN/GA showed that diroximel fumarate was associated with improvements in radiological and clinical endpoints over one year compared to baseline. Adjusted annualized relapse rate was reduced by 72% with diroximel fumarate between baseline and Week 48. Additionally, the mean number of gadolinium-enhancing, or Gd+, lesions was reduced by 64% with diroximel fumarate compared to baseline and the percentage of patients with no Gd+ lesions at Week 48 was 89% compared to 74% at baseline. Additional new data illustrate the tolerability profile of diroximel fumarate in relapsing-remitting MS patients over one year. In the study, diroximel fumarate demonstrated low rates of gastrointestinal, or GI, adverse events leading to discontinuation. The incidence of GI adverse events in patients treated with diroximel fumarate over the one-year treatment period was 30.9%. The GI events were generally mild or moderate in severity, typically appeared within the first month of treatment and tended to resolve quickly in the vast majority of patients. The data presented at CMSC add to the current knowledge base of diroximel fumarate and the interim results Biogen shared at the American Academy of Neurology annual meeting earlier this month on the potential safety and effectiveness of diroximel fumarate in relapsing MS, particularly in newly diagnosed patients. In addition, the GI tolerability of diroximel fumarate as compared to dimethyl fumarate is being evaluated in the ongoing EVOLVE-MS-2 study, with results expected later this year.

07:34 EDT Cytokinetics renews partnerships with ALS Association - Cytokinetics announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its gold level sponsorship of the National Walks to Defeat ALS and premier level National ALS Advocacy Conference sponsorship as well as platinum level sponsorship for initiatives led by The ALS Association Golden West Chapter, including grant funding for care services for people with ALS in the Bay Area.

07:32 EDT CGI Group appoints Energir CEO Sophie Brochu to board of directors - CGI announced the appointment of Sophie Brochu as a new member of its Board of Directors. Sophie Brochu is president and CEO of Energir.

07:14 EDT Zafgen announces regulatory update on ZGN-1061 - Zafgen announced the receipt of minutes from its Type A meeting with the FDA regarding the clinical hold for ZGN-1061. Zafgen provided new data in advance of the meeting, including newly developed in vitro assays of human plasma coagulation using endothelial cells and assessment of tissue factor expression with endothelial cells and other supportive new assays. The company is working with FDA to gain alignment on an in vivo animal model to confirm relevant safety margins as a next step toward resolving the clinical hold. Zafgen will be prepared to rapidly implement the agreed upon work. Additionally, the company is evaluating serious, rare disease indications that have few or no approved therapies in which ZGN-1061 could potentially benefit patients. The FDA was supportive of Zafgen seeking guidance on a second investigational new drug application for ZGN-1061, as appropriate. Zafgen will provide an update on development plans by the end of Q3.

07:07 EDT Harsco's Metals and Minerals division rebranding as Harsco Environmental - Harsco is rebranding its Metals and Minerals division as Harsco Environmental. This new name and visual identity are meant to more closely align with the company's focus on providing environmental services and product offerings to help customers drive business performance and growth. The name change and new branding take effect immediately. Harsco Environmental will continue to be led by Harsco Chairman & CEO Nick Grasberger in tandem with the division's COO Russ Mitchell. Harsco Environmental operates more than 130 sites in 32 countries and has 7,700 employees. It is Harsco's largest division, representing approximately 65% of revenue last year.

07:07 EDT Duke Energy announces plan to decommission retired Florida plant by 2027 - Duke Energy announced a plan to decommission its previously retired Crystal River Nuclear Plant in Florida by 2027 - nearly 50 years sooner than originally scheduled. The plan has no impact on customer bills. Duke Energy's accelerated decommissioning plan is subject to approval by the U.S. Nuclear Regulatory Commission and the Florida Public Service Commission. The process will take about a year to complete. If approved, decommissioning work will begin in 2020 and end in 2027. Duke Energy previously announced its decision to retire the plant on Feb. 5, 2013, and to decommission it by 2074. To perform the work, Duke Energy has contracted with Accelerated Decommissioning Partners, a joint venture between NorthStar Group Services and Orano USA. The contract structure provides Duke Energy customers financial protection and transfers project execution risks to Accelerated Decommissioning Partners, including potential cost overruns and unknown conditions. Accelerating the decommissioning also allows for faster restoration and redevelopment of the nuclear plant property for Duke Energy's reuse one day. The company has not yet determined how it might repurpose the property but has no plans to sell it. The company said, "Duke Energy is pursuing accelerated decommissioning for two reasons. First, the trust fund that pays for the decommissioning, a Nuclear Regulatory Commission requirement, is currently sufficient to accelerate the plant's decommissioning without increasing customer bills. Duke Energy's trust fund had about $717 million as of March 31, 2019. Accelerating the nuclear plant's decommissioning also gives Duke Energy a potential opportunity to return the majority of unused trust fund dollars back to customers more than three decades sooner than the current 60-year decommissioning model. Second, Duke Energy has cost-effectively completed the initial phase of decommissioning, placing the plant in an ideal condition to attract bidders to complete the work. This progress, coupled with increased competition in the industry, has lowered decommissioning costs, making the accelerated model financially feasible."

07:03 EDT J.D. Power partners with SurveyMonkey to expand customer data collection - J.D. Power has formed a partnership with SurveyMonkey to expand customer experience data collection through digital consumer channels. J.D. Power will leverage SurveyMonkey's innovative digital platform and SurveyMonkey Audience, the company's robust market research solution, to unlock insights from new customer segments.

06:54 EDT Reata Pharmaceuticals enrolls first patient in Phase 3 FALCON trial - Reata Pharmaceuticals announced the enrollment of the first patient in the Phase 3 FALCON trial of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease, or ADPKD.

06:37 EDT Rogers Communications subsidiary announces exclusive partnership with Contobox - Rogers Media and Contobox announced an exclusive partnership with the launch of R.E.D. Contobox, a data-driven advertising platform. The announcement comes as Rogers Media unveiled its 2019/2020 prime-time schedule, just ahead of Rogers Media Sales' upcoming agency presentations. Powered by Rogers enabled data, or R.E.D., and Contobox's ad technology platform, R.E.D. Contobox is sold by engagement vs. a traditional CPM model. R.E.D. Contobox will be represented exclusively to Canadian ad agencies as part of Rogers media sales' R.E.D. first-party data solutions. Agencies will be able to take advantage of R.E.D. Contobox both as a managed and programmatic service.

06:33 EDT Apple defends App Store amid increasing criticism - Apple defended its App Store from mounting criticism over its treatment of rivals in a new blog post detailing its functions and guidelines. In a section called "Principles and Practices," Apple defended its practices, saying developers decide what they want to charge from a set of price tiers. "We only collect a commission from developers when a digital good or service is delivered through an app." The company added that "We also care about quality over quantity, and trust over transactions. That's why, even though other stores have more users and more app downloads, the App Store earns more money for developers. Our users trust Apple - and that trust is critical to how we operate a fair, competitive store for developer app distribution." "We believe competition makes everything better and results in the best apps for our customers," the company added. Reference Link

06:06 EDT Melco Resorts & Entertainment purchases 19.99% stake in Crown Resorts - Melco Resorts & Entertainment announced that it executed a definitive purchase agreement through which a subsidiary of Melco will acquire 135.35M shares of Crown Resorts from CPH Crown Holdings for a price of A$13.00 per Crown share. These shares represent an ownership interest of approximately 19.99% in Crown. The transaction will close in two equal tranches on June 6 and on or prior to September 30. While the announced transaction does not require regulatory approval to be consummated, Melco, its chairman and CEO, Lawrence Ho, and select Melco executives will promptly submit applications to the gaming regulatory authorities in each of Victoria, Western Australia, New South Wales and any other relevant jurisdictions. Following approval from these authorities, Melco intends to pursue board representation on Crown's board of directors commensurate with its ownership position. Additionally, subject to obtaining requisite regulatory approvals, Melco welcomes the opportunity to increase its ownership in Crown.

05:44 EDT Achieve Life Sciences granted U.S. patent for cytisinicline formation - Achieve Life Sciences announced that the United States Patent and Trademark Office has granted Achieve a patent on succinate salt of cytisinicline and use thereof. The patent covers a novel salt form of cytisinicline, namely cytisinicline succinate, and pharmaceutical compositions and dosage forms. The U.S. Patent follows the grant of the same invention in the United Kingdom. Applications are pending in the European Patent Office, Japan, China, Australia, Canada, and South Korea.

05:14 EDT Novartis' phase III QUARTZ study meets primary, key secondary endpoints - Novartis announced the first study results from the phase III PLATINUM clinical development program assessing the safety and efficacy of QMF149, an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate and mometasone furoate. In this multicenter, randomized, double-blind phase III QUARTZ study, once-daily, low dose IND/MF 150/80 Mu g met the primary and key secondary endpoints when compared to once-daily mometasone furoate, an ICS, delivered via the Twisthaler device in both adult and adolescent patients with asthma. "Despite the number of available treatments, many patients' lives remain impacted by their asthma," said Linda Armstrong, MD, Respiratory Development Unit Head. "The QMF149 results of the QUARTZ study complement the recently presented phase II data of QVM149 at the 2019 American Thoracic Society Congress, showing superiority of QVM149 to the current standard of care. We look forward to seeing the rest of the data from the PLATINUM clinical trial program."